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TREATMENT PATTERNS AMONG NEWLY
DIAGNOSED CORONARY HEART DISEASE
PATIENTS: CORRELATES OF LIPID
MANAGEMENT
Watson-Heidari T1, Ershoff D2, Stacy J1, O’Donnell JC2,
Schmaltz S1, McDonough KL2, Sandman T1
1Humana Inc, Louisville, KY, USA; 2AstraZeneca LP, Wayne,
PA, USA
OBJECTIVES: In support of secondary prevention
efforts, NCEP guidelines have afﬁrmed the importance of
intensive management of LDL cholesterol in established
CHD patients. The objective of this retrospective, cohort
analysis was to examine correlates of “optimal” lipid
management among newly diagnosed CHD patients. 
The population was drawn from a health beneﬁts com-
pany under capitation (commercial, Medicare) and PPO
arrangements. METHODS: Eligible subjects (N =
10,125) had an index medical claim for CHD in Year
2000 (ICD-9 CM codes of 410–414, Procedure codes of:
36.0–36.3), no such diagnostic codes during a previous
24-month “clean” period, no pharmacy claims for a lipid-
lowering agent (LLA) in the six month period prior to the
index diagnosis, and continuous enrollment during the
36-month observation period. “Optimal” management
was deﬁned as at least 1 claim for a LLA in all four quar-
ters of a 12-month post-index follow-up period, coupled
with at least 1 lab claim associated with lipid monitoring
(lab values were not available for analysis). RESULTS:
Patients classiﬁed as receiving “optimal” management
equaled 4.9%, with 50.3% classiﬁed as receiving nei-
ther a lab claim nor a LLA. A logistic regression identi-
ﬁed ﬁve statistically signiﬁcant (P < 0.01) predictors of
“optimal” management, including: a) identiﬁcation by a
diagnosis of acute MI; b) age < 65 years; c) male gender;
d) a comorbidity of hypertension; and e) initial CHD
diagnosis by a physician other than a cardiologist/
cardiovascular surgeon. CONCLUSIONS: Effective lipid
management in patients with CHD has been linked to
reduced mortality, decreased morbidity and lower treat-
ment costs. Nonetheless, study ﬁndings identify a large
gap between the promise of pharmacotherapy and per-
formance in clinical practice. Increased promotion of
guidelines emphasizing the importance of aggressive lipid
management for both physicians and patients may be nec-
essary to decrease this gap and to achieve desired objec-
tives of secondary prevention of CHD.
PCV22
DISEASE MANAGEMENT REDUCES
HEALTHCARE DISPARITIES IN HEART 
FAILURE PATIENTS
Walker DR, Landis DL, O’Leary JS,Vance RP
CorSolutions, Buffalo Grove, IL, USA
OBJECTIVE: To provide evidence that a heart failure
(HF) disease management (DM) program can reduce dis-
parities in healthcare outcomes in minority populations.
METHODS: The study sample included HF patients who
were in a nurse-mediated DM program for at least 90
days, and who had a minimum of 2 quality of life (QOL)
and 2 NYHA measurements. QOL was measured for
both physical (PCS) and mental health (MCS) using the
SF-8 survey instrument. QOL and NYHA were measured
at the time of program enrollment and quarterly there-
after. Baseline QOL and NYHA scores were compared to
the most recent. The 95% conﬁdence interval for clinical
signiﬁcance is +/- 6.3 for MCS and +/- 5.7 for PCS. There
were 2578 patients in the sample, of which 2081 were
white and 497 were black. Blacks were signiﬁcantly
younger than whites (67 and 72 years of age), and were
more female (61% and 52%). RESULTS: The mean PCS
at baseline was 38.16 and 37.96, for whites and blacks
respectively. The mean PCS for the most recent scores was
41.39 (p < 0.0001) and 42.01 (p < 0.0001) respectively
for whites and blacks. Importantly, 39% and 45% of
whites and blacks had clinically signiﬁcant improvements
in PCS. The mean MCS at baseline was 46.44 and 47.28,
for whites and black respectively. The mean MCS for 
the most recent score was 47.84 (p < 0.0001) and 48.21
(p = 0.05) respectively for whites and blacks. Twenty
seven percent of both groups had clinically signiﬁcant
improvements in MCS. At baseline, 45% of whites and
only 35% of blacks were NYHA I or II. For the current
measurement 57% of whites and 59% of blacks were
NYHA I or II. CONCLUSIONS: Based upon these





A COST-BENEFIT MODEL FOR PERINDOPRIL IN
SECONDARY STROKE PREVENTION
Hartzema AG,Winterstein AG, Kwon SY
University of Florida, Gainesville, FL, USA
The PROGRESS trial demonstrated the effectiveness of
perindopril/indapamide in secondary stroke prevention
(SSP). No existing economic study has incorporated these
ﬁndings in a cost-beneﬁt analysis. OBJECTIVES: The
objective of this analysis was to evaluate the cost/beneﬁt
of perindopril/indapamide in SSP. METHODS: The
model used a decision tree approach to estimate direct
cost savings associated with SSP for a hypothetical cohort
of 10,000 ﬁrst stroke survivors from an HMO’s perspec-
tive (1 Mio covered lives) over a 3-year time period. Inci-
dence estimates for 2nd stroke and healthcare utilization
as well as pharmacoeconomic estimates are presented 
for each year and separated for the two major stroke
types (ischaemic and hemorrhagic stroke). First, stroke
incidence and transition probabilities for healthcare uti-
lization were abstracted from the published epidemio-
logic literature, incidence of second strokes from the
